SCHEMBL4096867

SCHEMBL4096867

COc1ccc(Cn2cc3nc(Cl)nc(OCc4ccccc4)c3n2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.47
CNR2 P34972 2/20 0.47
CYP19A1 P11511 2/20 0.46
ADORA3 P0DMS8 5/20 0.43
TP53 P04637 1/20 0.42
HRH4 Q9H3N8 1/20 0.42
ADORA2A P29274 2/20 0.41
ADORA1 P30542 2/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
GABRA1 P14867 2/20 0.41
GABRG2 P18507 2/20 0.41
GABRB3 P28472 2/20 0.41
GABRA5 P31644 2/20 0.41
GABRA3 P34903 2/20 0.41
GABRA2 P47869 2/20 0.41
SIGMAR1 Q99720 1/20 0.40
FAAH O00519 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17025280 0.86 TP53 (0.43) CNR2CYP19A1ADORA3TP53ADORA2A
SCHEMBL4103108 0.80 TP53 (0.44) CNR2CYP19A1ADORA3TP53ADORA2A
SCHEMBL25206891 0.79 ADORA3 (0.39) CNR1CNR2CYP19A1ADORA3TP53
SCHEMBL4101100 0.77 P2RX7 (0.38) CNR1CNR2CYP19A1TP53ALDH1A1
SCHEMBL23635091 0.77 HPGD (0.59) CNR1CNR2ADORA2A
SCHEMBL4102167 0.76 TP53 (0.37) CNR1CNR2CYP19A1TP53LMNA
SCHEMBL13734641 0.74 ADORA3 (0.58) ADORA3TP53ADORA2AADORA1ALDH1A1
SCHEMBL7567252 0.73 CYP19A1 (0.53) CNR1CNR2CYP19A1TP53ALDH1A1
SCHEMBL15650211 0.72 ADORA3 (0.49) ADORA3TP53ADORA2AADORA1
SCHEMBL14323257 0.71 ADORA3 (0.48) CNR2CYP19A1ADORA3TP53ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250082633-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC (US) 2025-03-13 US disclosed
CN-118804912-A Compounds and methods for modulating splicing 雷密克斯医疗公司 2024-10-18 CN disclosed
EP-4436961-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING Remix Therapeutics Inc. (US) 2024-10-02 EP disclosed
WO-2023097007-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. (US) 2023-06-01 WO disclosed
WO-2023097007-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. (US) 2023-06-01 WO disclosed
US-20090234117-A1 Pyrazolopyrimidine Derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-09-17 US disclosed
EP-1903045-A1 PYRAZOLOPYRIMIDINE DERIVATIVE Mitsubishi Tanabe Pharma Corporation (JP) 2008-03-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250082633-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING RBM17, SNRPA, SNRPA1 CNR1 4479/4885CNR2 4788/4885CYP19A1 2976/4885
US-20090234117-A1 Pyrazolopyrimidine Derivative MC2R, CRHR1, AVPR2 CNR1 89/4885CNR2 136/4885CYP19A1 1132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.